SARS-CoV-2 antibody responses in patients with acute leukaemia
Leukemia
.
2021 Jan;35(1):289-292.
doi: 10.1038/s41375-020-01103-2.
Epub 2020 Dec 9.
Authors
J O'Nions
1
,
L Muir
2
,
J Zheng
3
,
C Rees-Spear
2
,
A Rosa
4
,
C Roustan
4
,
C Earl
4
,
P Cherepanov
4
,
R Gupta
3
5
,
A Khwaja
3
5
,
C Jolly
2
,
L E McCoy
6
Affiliations
1
Department of Haematology, University College London NHS Foundation Trust, London, UK.
[email protected]
.
2
Division of Infection and Immunity, University College London, London, UK.
3
Department of Haematology, University College London NHS Foundation Trust, London, UK.
4
The Francis Crick Institute, London, UK.
5
UCL Cancer Institute London, Paul O'Gorman Building, London, UK.
6
Division of Infection and Immunity, University College London, London, UK.
[email protected]
.
PMID:
33299142
PMCID:
PMC7724438
DOI:
10.1038/s41375-020-01103-2
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Antibody Formation
COVID-19*
Humans
Immunoglobulin G
Leukemia, Lymphocytic, Chronic, B-Cell*
SARS-CoV-2
Substances
Immunoglobulin G
Grants and funding
WT_/Wellcome Trust/United Kingdom
108079/Z/15/Z/WT_/Wellcome Trust/United Kingdom
MR/R008698/1/MRC_/Medical Research Council/United Kingdom